CorMedix financials
$7.93+0.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $101.9M | $127.4M | $128.6M | $104.3M | $39.7M | $39.1M | $31.2M | $11.5M | $806.1K | $0.00 | $0.00 | $0.00 |
| Gross profit | $77.1M | $105.1M | $107.3M | $93.1M | $37.9M | $37.5M | $30.0M | $10.8M | $296.3K | -$818.5K | $0.00 | $0.00 |
| Gross margin | 75.7% | 82.5% | 83.4% | 89.3% | 95.3% | 95.9% | 96.2% | 94.0% | 36.8% | — | — | — |
| Operating income | $42.8M | $63.4M | $59.1M | $51.3M | $20.4M | $20.6M | $12.9M | -$3.3M | -$15.3M | -$16.7M | -$15.7M | -$10.5M |
| Net income | $26.0M | $38.6M | $14.0M | $108.6M | $19.8M | $20.6M | $13.5M | -$2.8M | -$14.2M | -$14.5M | -$14.8M | -$9.7M |
| Net margin | 25.5% | 30.3% | 10.9% | 104.1% | 49.9% | 52.8% | 43.2% | −24.2% | −1755.5% | — | — | — |
| Diluted EPS | $0.29 | $0.43 | $0.15 | $1.26 | $0.28 | $0.30 | $0.22 | $-0.05 | $-0.25 | $-0.25 | $-0.26 | $-0.17 |
| EBITDA | $53.4M | $73.9M | $69.6M | $55.1M | $20.5M | $20.8M | $13.1M | -$3.2M | -$15.2M | -$16.7M | -$15.7M | -$10.4M |
| Operating cash flow | $86.2M | $42.4M | $94.5M | $30.9M | $30.0M | $19.7M | -$5.6M | -$13.6M | -$14.0M | -$17.3M | -$10.7M | -$8.7M |
| Free cash flow | $85.7M | $41.7M | $92.7M | $30.4M | $30.0M | $19.7M | -$5.6M | -$13.7M | -$14.1M | -$17.4M | -$11.0M | -$8.7M |
| Diluted shares | 92.5M | 93.0M | 94.1M | 86.2M | 71.9M | 69.0M | 61.5M | 58.8M | 57.6M | 57.5M | 57.6M | 56.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $256.7M | $178.1M | $144.8M | $48.5M | $159.3M | $66.3M |
| Short-term investments | $0.00 | $0.00 | $3.7M | $7.2M | $31.4M | $11.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $1.1M | $0.00 | $0.00 |
| Total assets | $904.1M | $815.6M | $826.1M | $750.9M | $252.6M | $149.6M |
| Total liabilities | $443.2M | $378.6M | $420.8M | $376.7M | $32.0M | $34.7M |
| Shareholders' equity | $460.8M | $437.0M | $405.3M | $374.1M | $220.6M | $114.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology